



# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210 J, Shahpur Jat, New Delhi - 110 049 (INDIA)  
 Fax : 0091-11-26498341, 26494708, Phone : 0091-11-46181100, 46109900  
 CIN No. L74899DL1978PLC009181


## Statement of Standalone Unaudited Financial Results for the Quarter and Half Year Ended 30.9.2019

Rs. in lacs

Particulars	Standalone					12 Months Year Ended 31.03.2019 Audited
	Quarter Ended			Half Year Ended		
	30.09.2019	30.06.2019	30.09.2018	30.09.2019	30.09.2018	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	
<b>1 Income from operations</b>						
a Gross Sales/Revenue from	4180.59	4523.40	4412.49	8703.99	8652.89	16682.56
b Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
<b>Total Income from operations</b>	<b>4180.59</b>	<b>4523.40</b>	<b>4412.49</b>	<b>8703.99</b>	<b>8652.89</b>	<b>16682.56</b>
<b>2 Other Income</b>	<b>44.38</b>	<b>67.12</b>	<b>18.30</b>	<b>111.50</b>	<b>27.09</b>	<b>142.90</b>
<b>3 Total Income [ 1+2]</b>	<b>4224.97</b>	<b>4590.52</b>	<b>4430.79</b>	<b>8815.49</b>	<b>8679.98</b>	<b>16825.46</b>
<b>4 Expenses</b>						
a Cost of materials consumed	756.22	1173.13	990.99	1929.35	1841.55	3878.66
b Purchases of stock-in-trade	461.38	474.83	208.53	936.21	524.89	1464.08
c Changes in inventories of finished goods, work in progress and Stock in trade	371.10	201.11	766.19	572.21	1734.56	1941.82
d Excise Duty	0.00	0.00	0.00	0.00	0.00	0.00
e Employee benefits expenses	1246.90	1314.51	1264.76	2561.41	2327.18	4661.1
f Finance Cost	14.81	11.77	19.74	26.58	36.82	74.55
g Depreciation and amortisation	26.72	28.61	24.99	55.33	50.39	101.58
h Other expenses	1094.21	1136.10	934.35	2230.31	1852.44	3803.39
<b>Total expenses</b>	<b>3971.34</b>	<b>4340.06</b>	<b>4209.55</b>	<b>8311.40</b>	<b>8367.83</b>	<b>15925.18</b>
<b>5 Profit before exceptional items and taxes (3-4)</b>	<b>253.63</b>	<b>250.46</b>	<b>221.24</b>	<b>504.09</b>	<b>312.15</b>	<b>900.28</b>
6 Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
<b>7 Profit before tax [5-6]</b>	<b>253.63</b>	<b>250.46</b>	<b>221.24</b>	<b>504.09</b>	<b>312.15</b>	<b>900.28</b>
8 Tax expense	50.72	50.09	44.25	100.81	62.43	178.67
<b>9 Net Profit for the period [7-8]</b>	<b>202.91</b>	<b>200.37</b>	<b>176.99</b>	<b>403.28</b>	<b>249.72</b>	<b>721.61</b>
<b>10 Other Comprehensive Income</b>						
A (i) Items that will not be classified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
<b>11 Total Other Comprehensive Income [A(i) + A(ii)]</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>12 Total Comprehensive Income [9+11]</b>	<b>202.91</b>	<b>200.37</b>	<b>176.99</b>	<b>403.28</b>	<b>249.72</b>	<b>721.61</b>
13 Paid up Equity Share Capital (Face value Rs. 5/- per share)	1309.90	1309.90	1309.90	1309.90	1309.90	1309.90
<b>14 Earnings Per Share (before and after extraordinary items)</b>						
a. Basic (Rs.)	0.77	0.76	0.68	1.54	0.95	2.75
b. Diluted (Rs.)	0.77	0.76	0.68	1.54	0.95	2.75



Statement of Assets and Liabilities		
Particulars	As on 30.09.2019 (Unaudited)	As on 31.03.2019 (Audited)
<b>ASSETS</b>		
<b>1 Non-current assets</b>		
(a) Property , Plant and Equipment	2198.58	2161.39
(b) Capital Work-in-Progress	224.99	189.15
(c) Goodwill	3.00	3.00
development	206.27	206.27
(e) Financial assets		
(i) Investments	134.25	0.05
(f) Other non-current assets	1265.09	1262.72
<b>Total non-current assets</b>	<b>4032.18</b>	<b>3822.58</b>
<b>2 Current assets</b>		
(a) Inventories	2548.37	3269.26
(b) Financial assets		
(i) Trade receivables	2872.95	2075.02
(ii) Cash and Cash equivalents	51.57	35.70
above	4425.31	3817.76
(c) Other current assets	581.19	558.09
<b>Total current assets</b>	<b>10479.39</b>	<b>9755.83</b>
<b>TOTAL ASSETS</b>	<b>14511.57</b>	<b>13578.41</b>
<b>EQUITY AND LIABILITIES</b>		
<b>EQUITY</b>		
(a) Equity Share Capital	1309.90	1309.90
(b) Other Equity		
(i) Reserves & Surplus	9540.69	9137.41
<b>Total Equity</b>	<b>10850.59</b>	<b>10447.31</b>
<b>LIABILITIES</b>		
<b>1 Non-current liabilities</b>		
(a) Deferred tax liabilities (Net)	311.91	311.91
(b) Non current borrowings	0.00	0.00
<b>Non-current liabilities</b>	<b>311.91</b>	<b>311.91</b>
<b>2 Current Liabilities</b>		
(a) Financial Liabilities		
(i) Trade payables	1410.37	1186.04
(ii) Short term borrowings	448.98	378.54
(b) Other current liabilities	694.26	559.97
(c) Provision for tax	795.46	694.64
<b>Total current liabilities</b>	<b>3349.07</b>	<b>2819.19</b>
<b>Total Liabilities</b>	<b>3660.98</b>	<b>3131.10</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>14511.57</b>	<b>13578.41</b>



**Statement of Unaudited Cash flows for the Half Year Ended 30th September 2019**

	Particulars	Standalone	
		Unaudited	Audited
		Six Months ended Sep 30,2019	Year ended March 31,2019
<b>A.</b>	<b><u>Cash flow from operating activities</u></b>		
	Profit before taxation	504.09	900.28
	Adjustments to reconcile profit & loss to net cash provided by operating activities:		
	Depreciation and amortisation	55.33	101.58
	Finance costs	26.58	74.55
	Other Income	-111.50	-142.90
	<b>Operating profit before working capital changes</b>	<b>474.50</b>	<b>933.51</b>
	Adjustments for:		
	(Increase)/Decrease in Trade and Other Receivables	797.93	-440.34
	(Increase)/Decrease in Financial Assets & Other Non Current Assets	2.37	178.49
	(Increase)/Decrease in Inventories	-720.89	-1874.12
	(Increase)/Decrease in Current assets	23.10	206.77
	(Increase)/Decrease in Trade and Others Payables	-459.44	-412.40
	<b>Net Cash generated from /(used) in Operating Activities</b>	<b>356.93</b>	<b>2341.60</b>
	Taxes (Paid)/ Refund (net)	-100.81	-185.28
	<b>Net Cash generated from /(used) in Operating Activities</b>	<b>730.62</b>	<b>3089.83</b>
<b>B.</b>	<b><u>Cash flow from investing activities</u></b>		
	Capital expenditure on fixed assets	128.35	225.49
	Other Income	-111.50	-142.90
	Investments	134.20	
	<b>Net cash flow from / (used in) investing activities (B)</b>	<b>151.05</b>	<b>82.59</b>
<b>C.</b>	<b><u>Cash flow from financing activities</u></b>		
	Net increase / (decrease) in working capital borrowings	46.44	-231.43
	Proceeds from other short-term borrowings	23.99	-220.08
	Repayment of other short-term borrowings		
	Finance cost	-26.58	-74.55
	Change in Foreign Currency Translation Reserve		
	Impact of Deferred Tax Assets on Foreign Currency Translation		
	Dividend paid	0.00	-65.50
	Dividends Tax paid	0.00	-13.46
	<b>Net cash generated from / (used in) financing activities C</b>	<b>43.85</b>	<b>-605.02</b>
	<b>Net increase / (decrease) in Cash and cash equivalents (A+B+C)</b>	<b>623.42</b>	<b>2402.22</b>
	Opening Balance of Cash and Cash equivalents	3853.46	1451.24
	Closing Balance of Cash and Cash equivalents	4476.88	3853.46
	<b>Net increase / (decrease) in Cash and cash equivalents</b>	<b>623.42</b>	<b>2402.22</b>



Notes

1. The above Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on November 14, 2019.
2. In line with the provisions of Ind AS 18 , the Company operates in one reportable business segment i.e. 'Pharmaceuticals'.
3. Figures for the previous periods have been regrouped , wherever necessary, to correspond with the figures of the current period
4. The above results are available on website of the company [www.jagsonpal.com](http://www.jagsonpal.com) and on the Website of BSE ([www.bseindia.com](http://www.bseindia.com)) and NSE ([www.nseindia.com](http://www.nseindia.com)).
5. The Company has adopted Ind AS from April 1, 2017 and accordingly, these financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act 2013, read with relevant rules issued thereunder.
6. The revenue for the quarter ended 30-9-2019, is reported net of GST.

Provision for taxation includes provision for current tax.

Place : New Delhi  
Date : 14-11-2019



By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

*Rajpal Singh Kochhar*  
Rajpal Singh Kochhar  
Managing Director  
DIN No 00059492